News

Vaxxas has landed $90 million in debt and equity funding to develop technology that could replace the flu jab and other ...
This month, we’re hearing from women leaders in biotech on the challenges they face and their vision for the future. Jill Milne, founder and CEO of Astria Therapeutics: “The challenges I face ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.